You are here: Industry Insights > Market News > Drug for children with spinal muscular atrophy too expensive, HSE says

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Drug for children with spinal muscular atrophy too expensive, HSE says

firstwordpharmaFebruary 23, 2019

Tag: HSE , Spinal Muscular Atrophy , Children

Favorites

The Health Service Executive has determined that the spinal muscle atrophy drug Spinraza is not cost-effective at its current price, The Irish Times reported Friday.
The HSE determined that the treatment could carry a cost of 20 million euros over five years, while it was not able to reach an accord with the manufacturer regarding a viable price.
The regulator noted that Spinraza would carry a cost of 600 000 euros for the first year and 380 000 euros for each successive year.
The HSE stated that it was "obligated to ensure that expenditure of this scale must represent evidence of clinical and cost-effectiveness."
Register as Visitor to CPhI China 2019!

Previous:Delhi HC sets aside govt ban on Lupin's anti-diabetic drug Gluconorm-30

Next:Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Drug for children with spinal muscular atrophy too expensive, HSE says | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Drug for children with spinal muscular atrophy too expensive, HSE says

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Drug for children with spinal muscular atrophy too expensive, HSE says

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>